Editorial: The evolving paradigms and treatments for primary biliary cholangitis-Authors' reply

Aliment Pharmacol Ther. 2024 Jan;59(2):282. doi: 10.1111/apt.17798.

Authors

Marlyn J Mayo¹, John M Vierling², Christopher L Bowlus³

Affiliations

¹ Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA.
² Department of Medicine, Section of Gastroenterology and Hepatology, Department of Surgery, Division of Abdominal Transplantation, Baylor College of Medicine, Houston, Texas, USA.
³ Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California, USA.

PMID: 38153281
DOI: 10.1111/apt.17798

No abstract available

Publication types

Editorial
Comment

MeSH terms

Cholangitis* / diagnosis
Cholangitis* / drug therapy
Cholangitis, Sclerosing*
Humans
Liver Cirrhosis, Biliary* / diagnosis
Liver Cirrhosis, Biliary* / drug therapy

Grants and funding

CymaBay Therapeutics